Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: J Immunol. 2012 Jul 13;189(4):1812–1825. doi: 10.4049/jimmunol.1200552

Figure 5.

Figure 5

Abrogation of SHP-1 still improves efficacy of adoptive immunotherapy when the tumor antigen is also expressed as a self-antigen in the liver. B6 and Alb:Gag mice (Thy1.2+) were injected with 5×106 FBL leukemia. After 5 days, mice were injected with Cy (180 mg/kg) and 5×106 Thy1.1+ TCRgag SHP-1+/+ or SHP-1−/− 3stim effectors. Recipients also received exogenous IL-2 (104 U/mouse/day i.p. for 10 days). A, At 7 days after T cell transfer, mononuclear blood cells were isolated from therapy recipients and analyzed for the percentage of CD8+ Thy1.1+ cells by FACs. Numbers in the FACs plots indicate the percentage of CD8+ Thy1.1+ cell of the total blood mononuclear cells. Data is representative of 10–12 mice per group. B, The percentage of donor T cells in the blood 7 days after transfer was significantly different between recipients of SHP-1+/+ and SHP-1−/− T cells in both wild type and Alb:Gag mice (P<0.05). C, Survival of B6 and Alb:Gag therapy recipients of TCRgag SHP-1+/+ and SHP-1−/− cells.